Welcome to our dedicated page for Pmv Pharmaceuticals news (Ticker: PMVP), a resource for investors and traders seeking the latest updates and insights on Pmv Pharmaceuticals stock.
PMV Pharmaceuticals, Inc. (PMVP) is a clinical-stage biopharmaceutical company pioneering precision oncology therapies targeting p53 mutations, a key driver in many cancers. This page provides investors and researchers with verified updates on clinical trials, regulatory milestones, and corporate developments.
Access real-time announcements including phase progressions for PC14586 and other pipeline candidates, financial disclosures, and strategic collaborations. Our curated repository ensures you stay informed about PMVP’s tumor-agnostic approach to reactivating p53’s tumor-suppressing function.
Key updates cover clinical data publications, FDA designations, and research partnerships advancing small-molecule therapeutics. Bookmark this page for streamlined access to PMVP’s progress in developing treatments that address unmet needs in genetically defined cancers.
PMV Pharmaceuticals (PMVP) announced preliminary results from its ongoing Phase 1/2 PYNNACLE trial of PC14586, targeting the p53 Y220C mutation in advanced solid tumors. The ASCO abstract highlights a 30% partial response rate in higher dose cohorts among 29 patients. The drug demonstrated a favorable safety profile with well-tolerated doses. Updated data will be presented on June 7, 2022, during an oral session at ASCO, followed by an investor event to discuss the findings. The trial indicates potential for PC14586 as a targeted therapy in oncology.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) reported Q1 2022 financial results, highlighting $294.8 million in cash and a net loss of $18.4 million. R&D expenses increased to $11.8 million, driven by advancing PC14586, a first-in-class p53 Y220C reactivator. General and administrative costs rose to $6.8 million, reflecting infrastructure growth as a public company. The company emphasized its focus on executing the Phase 1/2 PYNNACLE trial and presenting initial data at the 2022 ASCO meeting on June 7.
PMV Pharmaceuticals (PMVP) has announced that initial data from its ongoing Phase 1 study of PC14586 will be presented at the 2022 ASCO Annual Meeting. This investigational therapy targets patients with advanced solid tumors featuring a p53 Y220C mutation. The oral presentation is scheduled for June 7, 2022, at 9:45 AM CDT, under the title 'First-in-human study of PC14586.' PC14586 aims to restore the normal function of p53 proteins, pivotal in cancer suppression. Detailed insights will be shared regarding its progress in the clinical trial process.
PMV Pharmaceuticals (PMVP) has made significant progress in its Phase 1/2 trial of PC14586, targeting advanced solid tumors with p53 Y220C mutations. As of December 31, 2021, the company reported a cash position of $314.1 million, down from $361.4 million in 2020. The net loss for 2021 was $57.8 million, an increase from $34.4 million in 2020, largely due to higher R&D and G&A expenses. While patient enrollment continues on track, the company anticipates initial results from the trial in mid-2022, aiming to expand its pipeline with additional p53-targeting therapies.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) announced that CEO David H. Mack, Ph.D., will participate in a panel on lung cancer at the 42nd Annual Cowen Health Care Conference from March 7-9, 2022. The panel discussion is scheduled for March 9, 2022, from 9:10 AM to 10:10 AM EST. The company, focused on developing small molecule therapies targeting p53 mutations, aims to connect with institutional investors during the conference.
PMV Pharma was founded to innovate in oncology, leveraging over 40 years of research into p53 biology.
PMV Pharmaceuticals, a precision oncology company, announced that its CEO, David H. Mack, will participate in a Fireside Chat at the Guggenheim Healthcare Talks 2022 Oncology Day on February 9, 2022, at 10:30 am ET. This event will include one-on-one investor meetings, emphasizing PMV's focus on tumor-agnostic therapies targeting p53 mutants. The company is recognized for its groundbreaking work in p53 biology, established by co-founder Dr. Arnold Levine in 1979. For more details, visit PMV Pharma's website.
PMV Pharmaceuticals (Nasdaq: PMVP) announced the appointment of Kirsten Flowers to its Board of Directors, effective January 6, 2022. This change follows the resignation of Peter Thompson, M.D., who contributed to the company's growth and IPO success. Flowers brings extensive experience in oncology product launches and commercial strategy, previously serving as Chief Commercial Officer at Kura Oncology and leading Array Biopharma's first commercial launch. Her expertise is expected to enhance PMV's strategy as it advances its candidate PC14586 targeting p53 mutations.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a leader in precision oncology, announced that David H. Mack, Ph.D., will participate in a "Fireside Chat" at the Evercore ISI 4th Annual HealthCONx Conference from November 30 to December 2, 2021. The chat is scheduled for December 2, 2021, at 11:20 am ET. PMV Pharma specializes in developing small molecule therapies targeting p53 mutations, which are prevalent in about half of all cancers. This event will also include one-on-one investor meetings.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) reported its Q3 2021 financial results, highlighting significant developments in its lead candidate, PC14586, targeting p53 Y220C mutations. With a robust cash position of $326.3 million as of September 30, 2021, PMVP anticipates sufficient funds to support operations through 2023. However, the company recorded a net loss of $39.5 million for the first nine months of 2021, up from $24.0 million in the same period last year, driven by increased R&D and G&A expenses.
PMV Pharmaceuticals (Nasdaq: PMVP) has appointed Tim Smith as Senior Vice President, Head of Corporate Development. Smith brings extensive experience from previous leadership roles in biotechnology, including Verseau Therapeutics and IDEAYA Biosciences. His expertise is expected to enhance PMV's efforts in developing tumor-agnostic therapies targeting p53 mutants, crucial for many cancers. The company's lead candidate, PC14586, aims to reactivate the p53 protein in patients with specific mutations.
